Trevi Therapeutics, Inc. TRVI R2K
Healthcare · Biotechnology · United States
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
READ MORE ›$14.14
+117.20% 1Y
Market & Price
Market Cap
$2.01B
Current Price
$14.14
High / Low (52W)
$15.40 / $5.47
Beta
1.08
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.34
Price to Book
10.55
P/S
-
EV/EBITDA
-34.90
Dividend Yield
-
Profitability & Returns
ROCE
-23.31%
ROE
-33.59%
ROA
-23.02%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.09
EPS (TTM)
$-0.32
Balance Sheet & Liquidity
Debt/Equity
0.40
Quick Ratio
24.30
Current Ratio
24.75
Debt
$682.00K
Total Assets
$193.44M
Current Assets
$191.66M
Working Capital
$181.91M
Ownership
Promoter Holding
0.63%
Chg in Prom Hold
-
FII / Inst Holding
98.21%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$1.84B
Total Revenue (TTM)
-
EBITDA
$-52.63M
Free Cash Flow
$-28.53M
Operating Cash Flow
$-45.30M
Shares Outstanding
141.98M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
-15.56%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -15.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TRVI Trevi Therapeutics, Inc. R2K | 14.14 | - | $2.01B | - | -23.31% | -33.59% | - | -15.56% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.47M | 13.72M | 13.92M | 10.22M | 14.91M |
| Operating Income | -3.14M | -4.38M | -4.96M | -4.81M | -7.42M | -7.65M | -8.64M | -7.41M | -7.24M | -8.09M | -9.17M | -6.95M | -7.03M | -7.82M | -8.40M | -7.56M | -8.38M | -9.04M | -11.91M | -13.29M | -14.09M | - | -11.47M | -13.72M | -13.92M | -10.22M | -14.91M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.43M | -12.28M | -11.78M | -8.30M | -14.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00K | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.35M | -12.32M | -11.82M | -8.33M | -13.21M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.00K | -21.00K | -15.00K | -16.00K | -20.00K |
| Net Income | -4.05M | -4.86M | -5.65M | -4.80M | -7.35M | -7.37M | -8.47M | -7.38M | -7.38M | -8.37M | -9.79M | -7.25M | -7.33M | -8.05M | -8.27M | -6.40M | -7.14M | -7.70M | -10.90M | -12.35M | -13.24M | - | -10.34M | -12.30M | -11.80M | -8.32M | -13.19M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.49 | -0.34 | -0.24 | -0.14 | -0.12 | -0.06 | -0.07 | -0.08 | -0.11 | -0.12 | -0.13 | - | -0.09 | -0.09 | -0.08 | -0.06 | -0.09 |
| R&D Expense | 2.36M | 3.44M | 3.75M | 3.34M | 5.53M | 5.65M | 6.02M | 4.92M | 4.83M | 5.59M | 6.50M | 4.72M | 4.64M | 5.10M | 5.77M | 5.00M | 5.84M | 6.32M | 8.80M | 10.02M | 11.22M | - | 7.81M | 9.39M | 10.09M | - | 9.94M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 29.91M | 33.92M | 51.52M | 49.33M |
| Operating Income | -18.41M | -26.64M | -32.49M | - | -29.91M | -33.92M | -51.52M | -49.33M |
| EBITDA | - | - | - | - | -27.98M | -28.58M | -47.79M | -42.68M |
| Interest Expense | - | - | - | - | 1.16M | 391.00K | 4.00K | 0 |
| Pretax Income | - | - | - | - | -29.19M | -29.10M | -47.94M | -42.82M |
| Tax Provision | - | - | - | - | -36.00K | -32.00K | -30.00K | -64.00K |
| Net Income | -20.55M | -26.05M | -32.76M | - | -29.15M | -29.07M | -47.91M | -42.76M |
| Diluted EPS | - | - | - | -1.49 | -0.45 | -0.29 | -0.47 | - |
| R&D Expense | 14.07M | 19.34M | 22.33M | 22.98M | 19.83M | 23.68M | 39.38M | 33.48M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -15.56% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +117.20% |
| 6 Months: | +24.47% |
| 3 Months: | +18.62% |
| 1 Month: | +2.32% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 10.53M | 60.00M | 47.13M | - | 123.02M | 89.40M | 110.90M | 193.44M |
| Current Assets | - | - | - | - | - | 122.62M | 87.55M | 109.43M | 191.66M |
| Cash & Equivalents | - | 7.20M | 57.31M | 45.00M | - | 12.59M | 32.40M | 34.10M | 18.91M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 241.00K | - | - | - | - |
| Total Liabilities | - | - | - | 19.85M | - | 15.56M | 6.86M | 11.26M | 10.20M |
| Current Liabilities | - | 2.68M | 5.20M | 5.55M | - | 13.40M | 5.82M | 10.51M | 9.75M |
| Long Term Debt | - | - | - | - | 8.65M | 2.15M | - | - | - |
| Total Debt | - | - | - | - | - | 9.18M | 1.34M | 1.03M | 753.00K |
| Total Equity | -84.43M | -109.49M | 54.55M | 27.28M | - | 107.46M | 82.55M | 99.64M | 183.24M |
| Shares Outstanding | - | - | - | - | - | 59.94M | 68.28M | 93.60M | 128.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -18.29M | -23.09M | -29.00M | - | -28.18M | -31.71M | -38.26M | -42.09M |
| Investing Cash Flow | -158.00K | -9.00K | -32.00K | - | -107.37M | 59.43M | -21.53M | -94.11M |
| Financing Cash Flow | 3.63M | 73.21M | 16.72M | - | 111.31M | -7.91M | 61.48M | 121.01M |
| Capital Expenditure | -158.00K | -9.00K | -32.00K | - | -159.00K | -137.00K | -35.00K | -12.00K |
| Free Cash Flow | -18.45M | -23.10M | -29.03M | - | -28.33M | -31.85M | -38.29M | -42.10M |
| Net Change in Cash | - | - | - | - | -24.24M | 19.81M | 1.70M | -15.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 18.8% | -47.8% | -120.1% | - | -27.1% | -35.2% | -48.1% | -23.3% |
| ROCE % | -234.5% | -48.6% | -78.1% | - | -27.3% | -40.6% | -51.3% | -26.9% |
Shareholding Pattern
Insiders
0.63%
Institutions
98.21%
Public Float
98.83%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | NEA Management Company, LLC | 9.31% | 13.22M | $186.96M |
| 2 | Blackrock Inc. | 7.21% | 10.24M | $144.80M |
| 3 | Frazier Life Sciences Management, L.P. | 7.00% | 9.94M | $140.55M |
| 4 | FMR, LLC | 5.66% | 8.04M | $113.66M |
| 5 | Wellington Management Group, LLP | 3.65% | 5.19M | $73.37M |
| 6 | Vivo Capital, LLC | 3.59% | 5.09M | $72.04M |
| 7 | Vanguard Capital Management LLC | 3.51% | 4.98M | $70.40M |
| 8 | Marshall Wace LLP | 2.79% | 3.97M | $56.08M |
| 9 | Rubric Capital Management LP | 2.61% | 3.71M | $52.49M |
| 10 | MPM Bioimpact LLC | 2.32% | 3.30M | $46.64M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRVI
No recent headlines available.